DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy.

The DRGs status is therapeutically meaningful in t-NEPC. Given the potential responses to platinum-based chemotherapy, our findings support the clinical use of NGS in t-NEPC patients to identify DRGs aberrations.